<DOC>
	<DOCNO>NCT00533221</DOCNO>
	<brief_summary>The purpose study determine whether Growth hormon increase strength spinal muscular atrophy type II III .</brief_summary>
	<brief_title>Pilot Study Growth Hormon Treat SMA Typ II III</brief_title>
	<detailed_description>This pilot study plan placebo-controlled cross-over trial limit number patient . It aim investigate effect GH short-term change strength investigate tolerability treatment . If result study positive , study longer duration address development motor function quality life could follow</detailed_description>
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Muscular Atrophy , Spinal</mesh_term>
	<mesh_term>Muscular Atrophy</mesh_term>
	<mesh_term>Spinal Muscular Atrophies Childhood</mesh_term>
	<criteria>genetically confirm diagnosis Spinal Muscular Disease Spinal muscular atrophy type II III age 6 year 35 year ability perform test measurement muscle strength ( handheld myometry ) inform consent patient and/or parent pregnancy lactation woman child bear potential without contraception overweight BMI 30 kg/mÂ² Treatment drug , influence strength 8 week participation study participation medical history evidence malignant cerebral tumor cardiovascular , intestinal , endocrinologically airway disease Hypertension growth hormone deficiency hypersensitivity one component part study medication participation clinical trial study 3 month abuse drug alcohol patient incapable contract able understand character , mean consequence clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>growth hormone</keyword>
	<keyword>strength</keyword>
	<keyword>Spinal muscular atrophy type II III</keyword>
</DOC>